Zydus Cadila has received the final approval from the USFDA to market Oxybutynin Chloride Extended-Release Tablets in the strengths of 5 mg, 10 mg, and 15 mg. The drug is used to treat symptoms of overactive bladder and urinary incontinence (urine leakage) and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad. The estimated sale for Oxybutynin Chloride Extended-Release Tablets is $150.9 million.
The group now has more than 120 approvals and has so far filed over 300 ANDAs, since the commencement of the filing process in FY 2003-04.
